<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204719">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000252</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-08391-4</org_study_id>
    <secondary_id>R01DA008391</secondary_id>
    <secondary_id>R01-08391-4</secondary_id>
    <nct_id>NCT00000252</nct_id>
  </id_info>
  <brief_title>Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4</brief_title>
  <official_title>Lack of Acute Tolerance Development to Effects of Nitrous Oxide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to conduct experiments to examine subjective and reinforcing
      effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug
      abusers and preference procedures will be used to assess reinforcing effects. To examine the
      lack of acute tolerance development to the subjective, cognitive, and psychomotor effects of
      nitrous oxide in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1994</start_date>
  <completion_date type="Actual">June 1996</completion_date>
  <primary_completion_date type="Actual">June 1996</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Psychomotor performance</measure>
    <time_frame>During inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will undergo psychomotor testing during 120 min inhalation session of each intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive performance</measure>
    <time_frame>During inhalation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will under cognitive testing during 120 minute inhalation session of each intervention</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>0% N2O</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subjects will inhale 0% N2O</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10% N2O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will inhale 10% N2O</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20% N2O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will inhale 20% N2O</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30% N2O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will inhale 30% N2O</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40% N2O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will inhale 40% N2O</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0% N2O</intervention_name>
    <arm_group_label>0% N2O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% N2O</intervention_name>
    <arm_group_label>10% N2O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20% N2O</intervention_name>
    <arm_group_label>20% N2O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30% N2O</intervention_name>
    <arm_group_label>30% N2O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40% N2O</intervention_name>
    <arm_group_label>40% N2O</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please contact site for information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Zacny, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago, Anesthesia &amp; Critical Care</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yajnik S, Zacny JP, Young CJ, Lichtor JL, Rupani G, Klafta JM, Coalson DW, Apfelbaum JL. Lack of acute tolerance development to the subjective, cognitive, and psychomotor effects of nitrous oxide in healthy volunteers. Pharmacol Biochem Behav. 1996 Jun;54(2):501-8.</citation>
    <PMID>8743615</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>May 26, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nitrous oxide</keyword>
  <keyword>acute tolerance</keyword>
  <keyword>subjective effects</keyword>
  <keyword>psychomotor</keyword>
  <keyword>analgesia</keyword>
  <keyword>healthy volunteer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
